MAP2K7 and non-small cell lung carcinoma: MEK inhibition (MEKi) alone has insufficient clinical activity in KRAS mutant NSCLC, but preclinical evidence suggests that MEK inhibitors may potentiate immune checkpoint inhibitor (ICI) therapy.5